| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human LTB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于 **LTB抗体** 的参考文献及其简要摘要：
---
1. **文献名称**: *"Mucosal vaccines: novel advances in technology and delivery"*
**作者**: Yuki Y, Kiyono H
**摘要**: 该综述讨论了黏膜疫苗的开发，重点提到**LTB(大肠杆菌热不稳定肠毒素B亚单位)**作为疫苗载体的应用。研究表明，LTB抗体可增强黏膜免疫应答，并在口服或鼻内疫苗中促进抗原递呈。
---
2. **文献名称**: *"Antibody responses to the Escherichia coli heat-labile toxin in patients with cholera and enterotoxigenic E. coli infection"*
**作者**: Hoshino K, et al.
**摘要**: 通过检测霍乱和产肠毒素大肠杆菌(ETEC)感染患者的血清抗体，发现**LTB特异性抗体**可作为感染标志物，并揭示其与毒素中和能力的相关性，为疫苗设计提供依据。
---
3. **文献名称**: *"Neutralizing antibodies to LTB toxin: evaluation of protection in animal models"*
**作者**: Freytag LC, Clements JD
**摘要**: 研究通过动物模型评估**LTB中和抗体**的效力，发现高滴度抗体能有效阻断毒素与宿主细胞受体结合，显著降低腹泻发生率，支持LTB作为疫苗靶点的潜力。
---
4. **文献名称**: *"Oral immunization with plant-derived LTB protein induces systemic and mucosal antibody responses"*
**作者**: Lauterslager T, et al.
**摘要**: 利用转基因植物表达LTB蛋白进行口服免疫实验，结果显示实验动物体内产生**特异性IgA和IgG抗体**，证明植物源性LTB可触发系统性及黏膜免疫应答，为低成本疫苗提供新策略。
---
**注**：LTB(Heat-Labile Enterotoxin Subunit B)常被用于疫苗研究或毒素检测，上述文献涵盖其抗体在免疫保护、诊断及疫苗开发中的作用。如需具体文献年份或期刊，建议通过PubMed或Google Scholar进一步检索。
LTB (Lymphotoxin-beta), a member of the tumor necrosis factor (TNF) superfamily, plays a critical role in immune system regulation and lymphoid organ development. It forms a heterotrimer with lymphotoxin-alpha (LTα), binding to the LTβ receptor (LTβR) to activate signaling pathways involved in inflammation, cell survival, and lymphoid tissue organization. LTB is essential for the development of secondary lymphoid structures, including lymph nodes and Peyer’s patches, and modulates immune responses by influencing lymphocyte trafficking and stromal cell interactions.
Antibodies targeting LTB or its receptor have emerged as tools to study and therapeutically manipulate immune pathways. They are investigated in autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) and cancers, where aberrant LTβR signaling contributes to chronic inflammation or tumor microenvironment remodeling. By blocking LTB-LTβR interactions, these antibodies can suppress pro-inflammatory cytokine production, inhibit lymphoid neogenesis in diseased tissues, or disrupt survival signals for malignant cells. Additionally, LTB antibodies serve as research reagents to dissect the physiological roles of the LTβ pathway in mucosal immunity, host defense, and lymphoid organ maintenance. Challenges include balancing therapeutic efficacy with potential immunosuppressive side effects, driving ongoing research into antibody engineering and targeted delivery strategies.
×
